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Children with Down’s syndrome (DS) have 20–50-fold
higher incidence of all leukaemias (lymphoid and mye-
loid), for reasons not understood. As incidence of many
solid tumours is much lower in DS, we speculated that
disturbed early haematopoietic differentiation could be the
cause of increased leukaemia risk. If a common mechan-
ism is behind the risk of both major leukaemia types, it
would have to arise before the bifurcation to myeloid and
lymphoid lineages. Using the transchromosomic system
(mouse embryonic stem cells (ESCs)) bearing an extra
human chromosome 21 (HSA21)) we analyzed the early
stages of haematopoietic commitment (mesodermal colony
formation) in vitro. We observed that trisomy 21 (T21)
causes increased production of haemogenic endothelial cells,
haematopoietic stem cell precursors and increased colony
forming potential, with signiﬁcantly increased immature
progenitors. Transchromosomic colonies showed increased
expression of Gata-2, c-Kit and Tie-2. A panel of partial
T21 ESCs allowed us to assign these effects to HSA21 sub-
regions, mapped by 3.5kbp-resolution tiling arrays. The
Gata-2 increase on one side, and c-Kit and Tie-2 increases on
the other, could be attributed to two different, non-
overlapping HSA21 regions. Using human-speciﬁc small
interfering RNA silencing, we could demonstrate that an
extra copy of RUNX1, but not ETS-2 or ERG, causes an
increase in Tie-2/c-Kit levels. Finally, we detected
signiﬁcantly increased levels of RUNX1, C-KIT and
PU.1 in human foetal livers with T21. We conclude that
overdose of more than one HSA21 gene contributes to the
disturbance of early haematopoiesis in DS, and that one of
the contributors is RUNX1. As the observed T21-driven
hyperproduction of multipotential immature precursors
precedes the bifurcation to lymphoid and myeloid lineages,
we speculate that this could create conditions of increased
chance for acquisition of pre-leukaemogenic rearrange-
ments/mutations in both lymphoid and myeloid lineages
during foetal haematopoiesis, contributing to the increased
risk of both leukaemia types in DS.
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Introduction
Dissection of the roles of individual genetic elements on
HSA21 in the pathogenesis of speciﬁc phenotype of
Down’s syndrome (DS) remains a challenge.
Children with DS, in the ﬁrst few years of life, have
approximately 50-fold higher overall incidence of
leukaemias than normal children, and this comprises
all types of acute myeloid leukaemia and acute
lymphocytic leukaemia (ALL) (Krivit and Good, 1957;
Hasle et al., 2000). Transient myeloproliferative disorder
(TMD) leading to acute megakaryoblastic leukaemia
(AMKL) account for more than half of all myeloid
leukaemias in DS, with an  500 increased incidence
relative to euploid children (Zipursky et al., 1994; Al-
Kasim et al., 2002; Taub and Ravindranath, 2002).
Among lymphoid leukaemias, the B-cell precursor ALL
is the most frequent type, but all other types also have
an increased incidence (Hasle et al., 2000; Forestier
et al., 2008; Hertzberg et al., 2010). The role of trisomy
21 (T21) and speciﬁc roles of a trisomic dose of
individual HSA21 genes in these increased leukaemia
risks are unknown.
Some aspects of both myeloid and lymphoid leukae-
mias in DS set them apart from leukaemias of the same
type in constitutionally euploid children (Malinge et al.,
2009): (i) T21 and in utero acquired mutations in the
transcription factor GATA1 are observed as always
co-existing in the proliferating cells of DS–TMD and
DS–AMKL (Wechsler et al., 2002; Groet et al., 2003;
Rainis et al., 2003); (ii) overexpression of the oncogene
MYCN is observed in DS-–TMD blasts (McElwaine
et al., 2004; Hitzler and Zipursky, 2005); and (iii) the
DS–ALL, despite being very heterogeneous (and partly
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acquired cytogenetic and molecular changes (Forestier
et al., 2008; Lundin et al., 2009), show an increased
acquisition of mutations in tyrosine kinase JAK2
(Bercovich et al., 2008; Kearney et al., 2009), and much
greater abundance of overexpression and rearrange-
ments in the cytokine receptor CRLF2 (Kearney et al.,
2009; Lundin et al., 2009; Russell et al., 2009; Hertzberg
et al., 2010), than non-DS–ALL. A hypothetical model
was proposed, by which T21 could provide a cell-
autonomous and embryonic-stage speciﬁc proliferative
advantage for GATA1 mutant clones (Li et al., 2005).
Forced massive overexpression of the HSA21 gene ERG
in cultured mouse foetal liver (FL) progenitors showed
the potential to cooperate with the GATA1 mutation
(Salek-Ardakani et al., 2009), boosting the proliferative
phenotype observed in mouse foetal haematopoiesis in
the absence of T21, in the GATA1 mutation-knock-in
mouse (Li et al., 2005). However, this model cannot
explain the increased risk in DS of other leukaemia types
(myeloid and lymphoid) that do not acquire GATA1
mutations.
Mouse models of DS (Kirsammer et al., 2008;
Carmichael et al., 2009; Alford et al., 2010) develop
extramedullary hyperproliferation of megakaryocytes,
which has been attributed to the third copy of ERG
(Ng et al., 2009), and not RUNX1 (Kirsammer et al.,
2008), and is unaffected by the simultaneous
introduction of GATA1 mutation (Alford et al., 2010).
Human FLs with T21 show abnormal myelopoiesis,
with an increased presence and proliferating propensity
of the megakaryocytic–erythroid progenitor compart-
ment, even in the absence of GATA1 mutations
(Chou et al., 2008; De Vita et al., 2008; Tunstall-Pedoe
et al., 2008). This evidence put together suggests a
general proliferative propensity conferred by T21 in
different haematopoietic compartments at different
stages in life.
The increased risk of malignancy in DS is not shared
by other tissues and organ systems: on the contrary,
most common cancers of solid tissues have a substan-
tially reduced incidence in DS, compared with
age-matched cohorts of euploid people (Satge et al.,
1998; Hasle et al., 2000; Yang et al., 2002). Epidemio-
logical data would suggest that chromosome 21 contains
genes with suppressive role in solid tumours. At least
one such gene, ETS-2, has been conﬁrmed to fulﬁl
tumour-suppressive role in colon cancer (Sussan et al.,
2008).
Because of this paradoxical relationship of T21
(tumourigenic in all types of leukaemias and tumour-
suppressive in most types of solid tumours), we decided
to investigate the effects of T21 on early haematopoietic
differentiation. We reasoned that any effect on this
process, in order to provide a common explanation
for the increased risk of both major leukaemia types,
would have to arise in the differentiation stages, before
the bifurcation to myeloid and lymphoid lineages,
in the early haematopoietic cell ontogeny. The ﬁrst cells
with a haematopoietic commitment can be detected
in vitro in mesodermal colonies, derived by differentiation
of mouse embryonic stem cells (ESCs) (Nakano
et al., 1994). This is why we focussed on the early
mesodermal colony formation in vitro, using the
transchromosomic system (mouse ESCs) bearing an
extra human chromosome 21 (HSA21) (Hernandez
et al., 1999)).
Though mouse ESCs differ from human ESCs in
some components of molecular circuitry, the effects of
the supernumerary human chromosome 21 in trans-
chromosomic mouse ESCs recapitulate many molecular
and cellular phenotypes observed in human cells from
T21 foeti: (i) transchromosomic ESCs show a reduction
in the levels of the RE-1 silencing transcription factor
(NRSF/REST) (Canzonetta et al., 2008), and reduced
neurogenesis with abnormally branching neurites
(Mensah et al., 2007; Canzonetta et al., 2008) as do
neural stem cells from human T21 foeti (Bahn et al.,
2002); (ii) the control of NRSF/REST levels can be
attributed to the HSA21 gene DYRK1A in transhromo-
somic ESCs, mouse neural progenitor cells and human
lymphocytes (Canzonetta et al., 2008; Lepagnol-Bestel
et al., 2009) and (iii) quantitative proteome changes
observed in transchromosomic ESCs recapitulate those
in human foetal tissues with T21 (Wang et al., 2009). In
addition, the transchromosomic ESCs provide a novel
genetic dissection system (something that cannot be
achieved even in human T21 iPS that has been recently
established (Park et al., 2008)), in allowing modelling of
selective reduction-to-disomy of individual supernumer-
ary HSA21 genes. This can be achieved using human-
speciﬁc small interfering RNA reagents, thereby exam-
ining the causative effects of the trisomy of one HSA21
gene at a time, while maintaining the rest of the
chromosome in trisomy (Canzonetta et al., 2008).
Results
Transchromosomic (T21) ESCs generate a higher
proportion of haemogenic endothelial cells than
wild-type ESCs
Haematopoietic differentiation of the transchromoso-
mic ESC line 47-1 that contains an entire HSA21 on the
background of the mouse ESC line D3 (Hernandez
et al., 1999) was achieved following an established
protocol (Era et al., 2000; Eto et al., 2003). Colonies at
day 5 of differentiation were harvested and analyzed for
the expression of several markers of the haematopoietic
stem cell (HSC) compartment and of haematopoietic
lineage progenitors (Akashi et al., 2000). Assessment of
the transcriptional proﬁle suggested that the predomi-
nant haematopoietic population within the colonies was
comprised of HSCs and lineage non-restricted cells
(Figure 1a). It had been shown that in vitro generation
of HSCs from ESCs proceeds through the formation of
a mesodermal precursor characterized by the onset of
expression of Flk-1 and Tie-2 (Shalaby et al., 1997;
Lugus et al., 2009), followed by the appearance of a
transient common precursor of the endothelial and
haematopoietic cells, the haemangioblast (Choi et al.,
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Oncogene1998). The haemangioblast has been identiﬁed in
‘in vivo’a n d‘ in vitro’ differentiation of both mouse
and human ES cells (Jaffredo et al., 2005; Park et al.,
2005), and has been recently shown to arise from the
haemogenic endothelial cells (Lancrin et al., 2009). At
the level of immunophenotype, these cells express high
levels of Tie-2 and c-Kit and are CD41 negative
(Lancrin et al., 2009).
In this study, we show that at day 5 of in vitro
haematopoietic differentiation, a stage characterized by
the formation of mesodermal colonies with haemato-
poietic potential, the transchromosomic ESCs line 47-1
presents an increase in expression of some markers
characteristic of the haemogenic endothelium when
compared with the parental cell line D3 (Figure 1bi
and ii). Flk-1 showed a substantial increasing trend,
though it did not reach statistical signiﬁcance, while Tie-
2 and c-Kit were both signiﬁcantly increased in T21 cells
(t-test, P-values¼0.02 and 0.009, respectively). Gata-2,
a master regulator of embryonic and early deﬁnitive
haematopoiesis (Lugus et al., 2007), was found to be
signiﬁcantly increased as well (t-test, P-value¼0.03).
The markers of committed endothelial cells Pecam and
Vegf were also compared between the differentiating
47-1 transchromosomic cells and the D3 parental cells,
and no difference in expression values was observed
(Figure 1biii). The increase in mRNA levels was also
reﬂected in an increase of the c-Kit
þCD41
  cell
population as shown by ﬂuorescence-activated cell
sorting analysis (Figures 1c and d, t-test, P¼0.009).
Taken together, these data suggest that mesodermal
colonies derived from 47-1 cells contain more inter-
mediate precursors with haematopoietic potential than
the control colonies.
As the data indicated that a supernumerary HSA21
affects levels of markers crucial to the ontogenesis of
HSCs, we reasoned that this should have consequences
on the functional ability of HSCs/immature haemato-
poietic progenitor cells. In order to examine this
hypothesis, we compared the þHSA21 (47-1) and
normal mesodermal colonies in their potential to
generate haemogenic progenitors by limited-dilution
assay (Figures 2a and b). Mesodermal colonies at day
5 of the differentiation protocol were trypsinized,
dissociated and replated at a density of 500 cells/plate
in a 96-well plate containing a fresh layer of OP9 cells
(Figure 2a). The number of haematopoietic colonies so
generated by the þHSA21 cells (47-1) was signiﬁcantly
higher than the control (D3) (Figure 2b, t-test,
P-value¼0.03). These data suggest that mesodermal
colonies derived from T21 ESCs generate an increased
proportion of haemogenic endothelial cells resulting in
the higher numbers of committed HSCs, than the
normal control ESCs.
Transchromosomic (T21) ESCs generate a higher
proportion of immature multipotent haematopoietic
progenitors than wild-type ESCs
Next, a colony-forming cell assay was performed to
compare the ability of the haematopoietic progenitors
derived from þHSA21 ESC (47-1) and the normal
parental cell line D3 to form colonies of different blood
lineages. We scored for colonies of three different types:
erythroid (BFU–E), granulocytes–macrophages (CFU–
GM) and mixed (CFU–GEMM) (schematic plan and
examples of colony morphology in Figure 2). The ability
of the trisomic haematopoietic progenitors to form
erythroid and myeloid colonies did not signiﬁcantly
differ from the control D3 progenitors. However, the
number of mixed colonies, which represents HSC-like
cells with secondary replating and self-renewal capacity
to generate multipotent haemogenic progenitors of
different lineages (Broxmeyer et al., 2003), was drama-
tically increased in 47-1 compared with the control
(Figure 2c, t-test, P-value o0.001). Together with the
increase observed in 47-1 cells in the limited dilution
experiment (Figure 2b), these ﬁndings strongly
argue that T21 increases the number of immature
multipotent haematopoietic progenitors generated
in vitro from ES cells.
Increases in c-Kit/Tie-2 and Gata-2 expression are
attributable to two separate regions on HSA21
In order to prove that the molecular changes observed
in 47-1 are not simply an artefact of a speciﬁc cell
line, we generated mesodermal colonies from other
Figure 1 Assessment of the transcriptional and cell-surface proﬁle of day 5 mesodermal colonies generated from transchromosomic ES cells:
T21 ESCs produce an increased number of haemogenic endothelial cells. (a) qRT–PCR measurements of mRNA levels of several markers of
the haematopoietic stem cell compartment (HSCs) and of lineage progenitors such as the common myeloid progenitors (CMP), the
granulocyte-macrophage progenitors (GMP) and the megakaryocyte-erythroid progenitors (MEP). Symbols depict relative amounts
of mRNA in each population relative to mGapdh: less than 0.001 (–); 0.001–0.01 (±); 0.01–0.1 (þ); 0.1–100 (þþ); 4100 (þþþ).
(b) qRT–PCR analysis of mRNA levels in day 5 mesodermal colonies derived from D3 and 47-1. Mean mRNA levels of the gene of interest are
expressed as fold changes of levels in D3 cells. Error bars indicate the s.e.m. (i) Markers of mesodermal differentiation. A signiﬁcant difference
was observed in the transcript levels Tie-2 (t-test; P-value¼0.02). Values are the mean of three and six independent experiments for Flk-1 and
Tie-2, respectively. (ii) Markers of the HSC/immature haematopoietic precursor compartment. A signiﬁcant difference was found in the
expression of c-Kit and Gata-2 between D3 and 47-1 (t-test; P-value¼0.009 and 0.03, respectively). Data shown are from nine independent
experiments. (iii) Markers of endothelial differentiation. No signiﬁcant difference in the levels of Pecam and Vegf was observed between
colonies derived from D3 and 47-1 at day 5 of differentiation. (c) FACS analysis of colonies derived from ESCs D3 and 47-1 at day 5 of
differentiation. Staining was performed with anti-CD41-FITC and anti-c-Kit-APC. Data were collected on a LSRII (BD Biosciences, Oxford,
UK) instrument and analyzed with FlowJo software version 8.1. Two-colour ﬂuorescence dot plots are shown for D3 and 47-1.
(d) Quantiﬁcation of the c-Kit
þCD41
  and of the c-Kit
þCD41
þ population. (i) is showing the frequency of c-Kit
þCD41
  cells and (ii) is
showing the frequency of c-Kit
þCD41
þ cells in both D3 and 47-1. The frequency of cells positive for c-Kit and negative for CD41 was
signiﬁcantly higher in the trisomic cells than in the control (t-test; P-value¼0.009). Data shown in both charts represents the average percentage
of three independent experiments. Error bars indicate s.e.m. A full colour version of this ﬁgure is available at the Oncogene journal online.
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Oncogenetranschromosomic ES cell lines carrying smaller por-
tions of HSA21 (43-Q, 40-2 and 46-1) (Hernandez et al.,
1999). A detailed analysis of the genomic content of
these cells was carried out using a high-resolution
comparative genomic hybridization array (HG-18-CHR21
tiling oligo arrays from NimbleGen (Waldkraiburg,
Germany) at 70bp average probe density interval, giving
a 3500-bp resolution). Examples of the tiling array
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Oncogenehybridization results for these lines can be seen in
Supplementary Figure S1. Figure 3a shows mRNA levels
of Tie-2, c-Kit and Gata-2 in mesodermal colonies derived
in parallel from the panel of partially trisomic ESCs. 43-Q
ESCs contain a very large proportion of the genes on
HSA21, but show two deletions, which affect more than
5Mb of HSA21 DNA. These cells present a molecular
signature that is very similar to that shown by 47-1 cells,
with levels of mRNA for Tie-2, c-Kit and Gata-2
signiﬁcantly increased compared with the parental D3
control (Figure 3a, t-test P-values¼0.03, 0.018 and 0.007,
respectively). 40-2 ES cells instead are characterized by
bigger deletions (Figure 3b), including genes known to
have a role in haematopoiesis, such as RUNX1, ERG and
ETS-2. Transcriptional analysis of day 5 colonies
generated by this cell line did not show upregulation of
mRNA levels for Tie-2 or c-Kit, but it kept the same
signiﬁcant increase in Gata-2 levels compared with the D3
euploid control (Figure 3aiii, t-test, P-value¼0.01). 46-1
ES cell line contains only a small 0.5-Mb stretch of
HSA21 comprising of ﬁve genes and did not reproduce
any of the phenotypes (Figure 3a). These data demon-
strate that alteration in the levels of mRNA for the
markers analyzed is not an artefact speciﬁc to the 47-1 cell
line, but is reproducible (totally or partially) in at least
three transchromosomic ES cell lines with a deﬁned
HSA21 content. Data also suggest that increase in c-Kit
and Tie-2 on one hand, and increase in Gata-2 on the
other hand, may represent two separate derangements,
caused by the action of genes on two different trisomic
regions on HSA21 during in vitro differentiation of ESCs
(Figure 3b).
Figure 2 Functional analysis of haematopoietic progenitors derived from the transchromosomic and the parental ES cell lines.
(a) Schematic of the assays used for the functional analysis of day 5 colonies derived from 47-1 (þHSA21) and D3 (euploid) ES cell
lines. In brief, the limited-dilution assay day 5 mesodermal colonies were treated with trypsin, counted and replated at a density of 500
cells/plate in a 96-well plate on a fresh layer of OP9 cells. The number of haematopoietic colonies generated from D3 cells and 47-1 cells
under these conditions was assessed at day 12. For the colony-forming assay, cells obtained from day 5 mesodermal colonies were
seeded on a fresh OP9 layer in 6-well plates. At day 8 of differentiation, the developing haematopoietic cells were harvested and plated
in methylcellulose-based medium supplemented with IL-3, IL-6 and EPO. Colonies were counted and classiﬁed according to
morphology on day 14. (b) Bar graph representing the average number of 47-1 (þHSA21) colonies relative to the average number of
D3 (euploid) colonies counted in ten 96-well plates (ﬁve independent cultures were seeded in duplicate). t-test P-value¼0.03, error bars
indicate s.e.m. (c) Colony-forming unit (CFU) assay. Bar chart showing the average number of myeloid colonies, erythroid colonies
and mixed colonies in three independent experiments, normalized in each case to the value obtained for the normal, D3 ESCs. Error
bars indicate s.e.m. A very high statistically signiﬁcant difference was detected between 47-1 (þHSA21) and D3 (euploid) cells in the
number of mixed colonies (t-test; P-valueo0.001). (d) Morphology of colonies generated from haematopoietic progenitors in semi-
solid medium supplemented with IL-3, IL-6 and EPO, following the Methocult protocol criteria. The ﬁgure shows the three types of
colonies scored at day 14 after seeding in semi-solid medium. Pictures were taken using a light microscope with an  20 objective.
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OncogeneA third copy of RUNX1, but not ERG or ETS-2,
is necessary for the c-Kit/Tie-2 increase
The effects of the increased c-Kit and Tie-2 levels in
mesodermal colonies were assigned to the trisomic dose
of HSA21 regions that include genes known to have a
prominent role in haematopoiesis, such as RUNX1,
ERG and ETS-2. Next, we decided to take advantage of
the possibility of restoring the diploid dose of one gene
at a time on HSA21 by speciﬁcally silencing its third
human copy, to test if the causative role for the
aberrantly high mesodermal colony transcript levels
could be pinpointed to any of the candidate genes. 47-1
ES cells were transfected with human-speciﬁc RNAi for
a given HSA21 gene or non-targeting RNAi control,
and allowed to differentiate up to the mesodermal
colony stage. After 5 days of differentiation, cells were
harvested, and RNA extraction and qRT–PCR were
performed. As can be seen in Figure 4a, the third human
copy of RUNX1 was effectively silenced, with little or
no effect on the level of mouse RUNX1 transcript, and
this silencing lasted at least for 3 days. Levels of
c-Kit were signiﬁcantly lower compared with the
Figure 3 Genetic dissection of HSA21 for the role in mesodermal colony haematopoietic disturbance using partially trisomic ES cell
lines. (a) Comparison of the molecular changes observed in þHSA21 ES cell line 47-1, across a panel of partially trisomic ESC lines,
43-Q, 40-2 and 46-1. Bar charts show the average mRNA levels of a minimum of three independent experiments. Data are represented
as fold change relative to levels in D3 parental cells. Error bars indicate s.e.m. Levels of Tie-2 and c-Kit mRNA were signiﬁcantly
upregulated in 43-Q, but not in 42-0 and 46-1 (i and ii), compared with the D3 control (t-test; P-value¼0.018 and 0.03, respectively).
(iii) Levels of Gata-2 mRNA were signiﬁcantly increased in both 43-Q and 42-0, but not in 46-1, compared with the D3 euploid control
(t-test; P-value¼0.007 and 0.01, respectively). (b) Characterization of HSA21 content of the transchromosomic ES cell lines. Data
obtained from HR–CGH array. Light grey bars indicate that a given gene on HSA21 is present in the ES cell line; white bars indicate
that the gene is absent. Regions that might be responsible for the increased Gata-2 and the increased c-Kit/Tie-2 phenotypes of
mesodermal colonies are highlighted in red and blue respectively. In purple are indicated other HSA21 genes that may be contributing
to the c-Kit and Tie-2 disturbance because of their published link with myelo-erythropoiesis.
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Oncogenenon-targeting control when hRUNX1 was silenced; Tie-
2 levels were diminished, but did not reach signiﬁcance,
while Gata-2 was unaffected (Figure 4b), as would be
predicted from the data obtained using the partial T21
ESC line panel (Figure 3). ERG and ETS-2 RNAi did
not show any signiﬁcant difference from the scrambled
RNAi controls (Supplementary Figure S2). Our data
therefore suggest that the third copy of RUNX1, but not
ERG or ETS-2, is necessary in the context of T21, to
account for the observed perturbation of c-Kit and Tie-2
in the early haematopoietic differentiation.
Human FLs with T21 have augmented levels of
haematopoietic markers compared with euploid controls
To gain insights into the correlates of the observed
molecular changes in human FL haematopoiesis, qRT–
PCR was used to quantify the level of expression of a
panel of genes in RNA extracted from primary samples.
Six T21 FLs were compared with euploid controls best
matched for sex and gestational age. Samples were
frozen tissues from therapeutically terminated T21 or
euploid pregnancies, and they were all from the second
trimester. Initially, all RNA samples were screened for
the presence of mutations or splicing changes in the
GATA-1 transcript by RT–PCR and sequencing (data
not shown), and all were found to have a wild-type
sequence for GATA-1. Markers analyzed included
CD34, C-KIT, CD41, PU.1, IGLL-1 and RUNX1
(Figure 5). These markers are expressed predominantly
or exclusively in haematopoietic lineage cells, and not in
other cell types in the FL. PU.1 is a marker of both
myeloid and lymphoid progenitor lineages, whereas
IGLL1 is strongly expressed only in pre-B lymphocyte
precursors, in a lineage-restricted manner. The expres-
sion level of CD34 mRNA was on the border of
detectability, and could not be quantiﬁed with con-
ﬁdence (not shown). RUNX1, PU.1 and C-KIT mRNA
levels were signiﬁcantly higher in the T21 FLs than in
the euploid controls (Figure 5, P-value¼0.01, 0.03 and
Figure 4 Effects of the reduction of RUNX1 to disomy in differentiating þHSA21 ESCs (a) (i) RT–PCR analysis performed on
cDNA extracted from untreated 47-1 (þHSA21), 47-1 transfected with RNAi oligonucleotides targeting hRUNX1 or with non-
targeting RNAi control at different time points. RT–PCR was performed on the same samples with primers speciﬁc for hRUNX1,
mRunx1 and mGapdh. Cells were harvested for total RNA extraction at the indicated time points after transfection. (ii) Western blot
performed on untreated 47-1, 47-1 transfected with oligos targeting hRUNX1 and non-targeting oligos. Nuclear extracts were
generated from cells harvested 72h after transfection. The membrane was probed with a mouse monoclonal antibody anti-RUNX1
and with a rabbit polyclonal antibody against the mouse nuclear protein EZH2 was used as a loading control. (b) The qRT–PCR
analysis of mRNA levels for c-Kit, Tie-2 and Gata-2 in day 5 mesodermal colonies derived from 47-1 cells, transfected with RNAi
targeting hRUNX1 or non-targeting RNAi control. The mRNA levels were measured 6 days post transfection. Bar charts represent
the mean mRNA levels normalized to mGapdh and relative to control samples transfected with non-targeting RNAi sequence (n¼3).
Error bars indicate s.e.m. There was a signiﬁcant reduction (t-test; P-value¼0.04) of the levels of c-Kit in the hRUNX1 RNAi
compared with the control.
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Oncogene0.04, respectively) using Wilcoxon’s signed-rank tests
performed on the six-matched pairs. CD41 and IGLL-1
showed a consistent trend to be higher in T21 than in
normal euploid samples, but did not reach statistical
signiﬁcance. Taken together, these data suggest that
the in vitro phenotypes we observed using mouse
transchromosomic ESCs (Figures 1–5) do represent a
valid model for some effects of T21 on human foetal
haematopoiesis.
Discussion
Increased levels of Gata-2 observed in mesodermal
colonies (Figure 1b), though only slightly over twofold,
could be responsible for the initial disturbance of
haematopoietic differentiation in our system. It has
been demonstrated that, with the same differentiation
protocol, using coculture with OP9 stromal cells,
conditionally induced overexpression of GATA-2 (ten-
fold) caused enhanced production of haemangioblasts
(Lugus et al., 2007) and haematopoietic progenitors
(Kitajima et al., 2002, 2006). The increase in Gata-2
mRNA levels by the 47-1, 43-Q and 40-2 cells, but not
46-1 ES cells (Figure 3a), is attributable to trisomy of
two different regions on HSA21 (Figure 3b, red
column). The distal of the two regions contains
DYRK1A, which has been previously shown to have
an effect on derangement of the pluripotency of ESCs
(Canzonetta et al., 2008). The proximal region corre-
sponds to the pericentromeric region, the same segment
Figure 5 Human FL with trisomy 21 shows increased levels of early haematopoietic markers. qRT–PCR analysis of mRNA levels for
RUNX-1, C-KIT, CD41, PU1 and IGLL-1 in FLs from Down’s syndrome (DS) and matched euploid controls. Data are presented as
ratios of mRNA levels for each DS and its matched euploid control. Signiﬁcance was calculated by Wilcoxon’s signed-rank test. Levels
of RUNX1, PU.1 and C-KIT were found to be signiﬁcantly higher in DS compared with euploid samples (P-value¼0.01, 0.03 and
0.04, respectively).
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Oncogeneof HSA21 that was found by multiple studies to harbour
frequent chromosome rearrangements and an increased
disomic homozygosity of the DNA markers in DS–
TMD and DS–AMKL, compared with DS without
leukaemia (Niikawa et al., 1991; Shen et al., 1995; Ohta
et al., 1996; Cavani et al., 1998; Korbel et al., 2009).
Conversely, trisomy of one or more genes, which are
present in 47-1 and 43-Q, but absent in 40-2 and 46-1,
is required for regulating the levels of Tie-2 and c-Kit.
Interestingly, among these genes there are some
important regulators of haematopoiesis and leukaemo-
genesis, such as ERG, ETS-2 and RUNX1 (Figure 3b,
blue column), which makes them natural candidates for
this role. Our RNAi data (Figure 4, Supplementary
Figure S2) suggest that the third copy of RUNX1, but
not ERG or ETS-2, is necessary in the context of T21 to
account for the observed perturbation of the early
haematopoietic differentiation. These results are in
concordance with data reported for the systems with
induced massive overexpression of these genes.
Although ERG was found, on massive overexpression
to promote megakaryopoiesis in the cell lines (Rainis
et al., 2005), and both ERG and ETS-2 were found to
cooperate with GATA1 mutation in boosting megakaryo-
cyte hyperproliferation (Salek-Ardakani et al., 2009;
Stankiewicz and Crispino, 2009), RUNX1 conditional
overexpression in vitro using the same OP9-based
differentiation system enhanced the production of
HSC and immature progenitors of all myeloid, and
most signiﬁcantly (on addition of Flt3-ligand) also
B-lymphocyte progenitors (Sakai et al., 2009). Haploin-
sufﬁciency of RUNX1 produces a mouse with reduced
HSC and early haematopoiesis (Cai et al., 2000). These
data combined with the presented results (Figures 2–5)
point to RUNX1 as a signiﬁcant candidate for the
contribution to the hypothetical common mechanism
behind the increased risk of myeloid and lymphoid
leukaemias in DS. When driven by the GATA1 promoter
in vivo, overexpression of RUNX1 was found to be pro-
leukaemogenic in the myeloid lineage, and it produced the
closest representation so far of a DS-TMD in a mouse
model: increased numbers of leucocytes and CD61
þ cells
in neonates, but not in 8-month-old mice (Yanagida et al.,
2005). We cannot rule out the contribution of other
HSA21 genes in the generation of the c-Kit and Tie-2
disturbance such as those marked purple in the list of
genes in Figure 3b, because of their published link
with myelo-erythropoiesis (Toki et al., 2005; O’Connell
et al., 2008; Klusmann et al., 2010) Encouragingly, our
in vitro phenotype using mouse ESCs has an in vivo
correlate in the human foetal haematopoiesis: CD34
þ
cells from FLs with T21 were recently reported to have a
markedly increased clonogenicity of several myeloid
lineage progenitors, including higher numbers and replat-
ing efﬁciency of the CFU–GEMM (mixed) immature
progenitors (Tunstall-Pedoe et al., 2008).
The increased levels of C-KIT that we ﬁnd in T21-FL
(Figure 5) would suggest that committed HSCs and/or
immature haematopoietic precursors are more numer-
ous in DS–FLs than in euploid controls, as the
expression of C-KIT in human FLs is restricted to the
CD38
þ stem cell compartment (Teyssier-Le Discorde
et al., 1999). Interestingly, a recent report has found that
the level of C-KIT and SCF/C-KIT signalling (proli-
ferative stimulation by SCF and inhibition by imatinib)
were signiﬁcantly increased in primary DS–TMD blasts
(Toki et al., 2009). The increased levels of RUNX1 that
we ﬁnd in T21 FLs appear to be highly signiﬁcant, and
on an average 45  the euploid liver value, (Figure 5),
overall much higher than would be predicted by a mere
1.5  trisomic increase. The RUNX1 level increase in
the range of 1.5  though on just a few samples, has
been reported for the isolated CD34
þ cells from human
T21 FLs (Tunstall-Pedoe et al., 2008). This suggests that
our result is more likely representing a much higher
overall proportion of RUNX1-expressing cells in the
T21 FLs, rather than a disproportionately increased
level of RUNX1 per cell. As only haematopoietic (HSC,
and differentiating myeloid and lymphoid) cells are
expected to express RUNX1 (Levanon and Groner,
2004), the data suggest that T21 FLs have much more
(3–4 ) active haematopoiesis than euploid controls. As
RUNX1 levels were not found to be disproportionately
increased in GATA1-mutated DS–TMD blasts (McEl-
waine et al., 2004), we suggest that the trisomic increase
of RUNX1 dose alone contributes to the initial
disturbance that sets off a stochastic pathogenetic
process.
Stochastic model of leukaemogenesis in DS
So far, the role of HSA21 genes in the pathogenesis of
DS–leukaemias is uncertain. One model postulates that
trisomic overdose of unknown HSA21 genes provides a
selective proliferative advantage for the clonal expan-
sion of cells that acquired pre-leukaemogenic mutations,
such as GATA1 in DS–AMKL/TMD or JAK2 in DS–
ALL (Li et al., 2005; Malinge et al., 2009). Recent
ﬁndings (Chou et al., 2008; De Vita et al., 2008;
Tunstall-Pedoe et al., 2008) suggest a model in which
hyperproliferative tendency of the megakaryocyte pre-
cursors caused by T21 precedes the accumulation of
GATA1 mutations (Tunstall-Pedoe et al., 2008). Com-
bining the data presented (Figures 1–5) with the existing
literature allows us to extend this view even further, and
hypothesize that the trisomic dose of different HSA21
genes contributes to an increased generation of im-
mature haemogenic precursors at multiple levels, acting
stochastically to increase the risk of acquisition of pre-
leukaemogenic and leukaemogenic mutations in both
lymphoid and myeloid branches (Figure 6). Following
from left to right, this diagram combines multiple lines
of evidence: (i) trisomy of DYRK1A disturbs ESCs
pluripotency and early stem cell fate with increased
markers of endodermal and mesodermal lineages
(Canzonetta et al., 2008); (ii) trisomy of either the
DYRK1A locus and/or the pericentromeric region, or
both, causes the increased levels of Gata-2 in mesoder-
mal colonies (Figures 1 and 3); (iii) overexpression of
Gata-2 causes an increase in the numbers of haemogenic
endothelial cells (Flk1
þTie-2
þc-Kit
þCD41
 ) (Lugus
et al., 2007) and (Figures 1 and 2), and it could even
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(due to the presence of Gata-2 at the RUNX1 promoter,
(Nottingham et al., 2007)); (iv) increased expression of
RUNX1 due to T21 alone, or in addition due to Gata-2
increase, drives stronger the commitment of haemogenic
endothelial cells to become HSCs (Zovein et al., 2008;
Chen et al., 2009; Lancrin et al., 2009; Sakai et al.,
2009), which is why the increase in the level of c-Kit
(representing the combined presence of haemogenic
endothelial cells and HSCs) can be corrected by the
reduction of RUNX1 back to disomy (Figure 4); (v) all
this results in increased clonogenicity of haematopoietic
progenitors in T21 FLs (Tunstall-Pedoe et al.,
2008), and specially accumulation (and increased self-
renewing potential) of immature precursors (Figure 5)
and multipotent CFU–GEMM, (Figure 2 and Tunstall-
Pedoe et al., 2008), as well as an increased capacity to
generate B-lymphocyte precursors (Sakai et al., 2009);
(vi) through increased dose of ERG, differentiation of
common myeloid progenitors is further skewed
towards megakaryocyte-erythroid progenitor lineage
(Rainis et al., 2005; Chou et al., 2008; Tunstall-Pedoe
et al., 2008) (vii) all these processes increase the chances
(‘cast dice’ symbol in Figure 6) for JAK2, CRLF2,
GATA1, JAK3 and other mutations to occur, causing
expansions of pre-leukaemic clones; and (viii) these
pre-leukaemic clones, (manifesting themselves as DS–
TMD, when associated with GATA1 mutations), can
either accumulate a variety of other tumourigenic hits
during early childhood, (similar to most non-DS
haematological malignancies) (Forestier et al., 2008;
Kearney et al., 2009; Russell et al., 2009), or sponta-
neously regress and disappear in adulthood. A notice-
able exception is the MLL rearrangements that
are actually lacking in DS–ALL, reﬂecting probably
another pathogenetic constraint conferred by T21 that
needs explanation. Clones with sufﬁcient numbers of
additional hits develop full ALL or acute myeloid
leukaemia (more than half of acute myeloid leukaemias
are GATA1-mutated acute megakaryoblastic leukae-
mias). The intensity of this stochastic regulation, as
well as the fate (nothing, regression, ALL or acute
myeloid leukaemia) could depend, in addition to
chance, on the subtle inter-individual differences in the
level of expression of the relevant HSA21 genes among
the DS individuals in population where the dispropor-
tionate net increase in speciﬁc gene(s) expression in a
subset of DS individuals could result from a high
expressing allele superimposed on the trisomic dose
increase (Prandini et al., 2007). Very sharp increases in
levels of haematopoietic markers seen in some T21 FL
samples (Figure 5), and great individual variability
between samples could reﬂect this explanation.
Importantly, human RUNX1 is missing from the list
of genes trisomic in the Tc1 mouse model of DS, as it
was among the 17% of genes deleted in the ESC line
Figure 6 Stochastic model of leukaemogenesis in Down’s syndrome (DS), pointing at multiple effects of several trisomic HSA21
genes. The HSA21 genes are shown in purple, measurable effects in red, multiple cell symbols signify hyperproliferation/increased
presence of the particular cell type, cast dice symbols represent increased chance of a mutagenic event occurring and the warning sign
symbolizes an acquired mutation that has occurred. Refer the ‘Discussion’ section in text for detailed explanation.
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Oncogeneused to generate the mouse (Alford et al., 2010), and the
pericentromeric HSA21 region is missing in other DS
mouse models that contain RUNX1 (Olson et al., 2004).
Therefore, the in vitro disturbance we observe could not
have fully contributed to any DS-leukaemia mouse
model analyzed thus far, as none of the models
contained all of the co-operating trisomic chromosomal
regions.
Materials and methods
Materials, cells and tissues
All general reagents, tissue-culture media and primers were
supplied by Sigma-Aldrich (Dorset, UK), unless otherwise
stated. Transchromosomic ES cells 47 1, 40-2, 43-Q and 46-1
were derived from D3 ES cells by the introduction of all, or
parts, of HSA21 via microcell-mediated chromosome transfer
(Hernandez et al., 1999). Sequences of primers used for
quantitative RT–PCR are available on request. Mouse
monoclonal anti-hRUNX1 antibody and rabbit polyclonal
anti-mouse EZH2 antibody were from Abcam (Cambridge,
UK). FLs were consented terminated human foetal tissue
collected by the Galliera Hospital’s Tissue Bank or the MRC
Foetal Tissue Bank. All archived material was consented for
use in research, and the project is covered by the ethical
approval from the North East London Health Authority.
ES Cell culture and differentiation
Pluripotent D3, 47-1, 40-2, 43-Q and 46-1 ES cells were
cultured as described (Canzonetta et al., 2008). Minimization
of background from feeder cells was obtained by pre-plating,
before differentiation or RNA extraction, for 45min onto non-
gelatine coated tissue culture ﬂasks. OP9 cells (ATCC
(Manassas, VA, USA) CRL-2749) were maintained in freshly
prepared minimum essential medium supplemented with 20%
foetal bovine serum (ATCC, 30-2021) and 2mML -glutamine.
Haematopoietic differentiation of the different ES cell lines
was performed as previously described (Era et al.,
2000; Kitajima et al., 2003). In brief, a conﬂuent layer
of OP9 cells was seeded in 6-well plates 16h before starting
the differentiation protocol. At day 0 each well of a
6-well plate was seeded with 5 10
4 ES cells in OP9 medium.
At day 5, cells were trypsinized, supplemented with fresh
OP9 medium and plated for 45min into T75 tissue culture
ﬂasks to remove the stromal cells. The supernatant was
collected and RNA was extracted with RNeasy Plus Mini Kit
(Qiagen, Crawley, UK).
Limiting dilution assay
Cells were harvested by treatment with trypsin at day 5 of
haematopoietic differentiation, counted and replated onto
a fresh OP9 feeder layer at a density of 5 10
2 cells/plate in a
96-well plate. At day 12, wells were scored under a light
microscope for the presence of haematopoietic colonies.
Colony-forming unit assay
At day 5 of the haematopoietic differentiation protocol, cells
were harvested, resuspended to a single cell suspension and
replated on a fresh OP9 feeder layer. Three days later, cells
were trypsinized again, counted and plated on a semi-solid
medium supplemented with cytokines (Methocult, M3434,
Stem Cell Technologies, Grenoble, France) at a density of
1 10
5/dish in 35mm dishes. Scoring of the colonies was
performed using a light microscope according to the manu-
facturer’s instructions.
RNAi silencing
RNAi control and transfection protocol were as previously
described (Canzonetta et al., 2008), see also Supplementary
Methods online.
Protein analysis
Immunoblot analyses were performed as described previously
(Delom et al., 2007), see also Supplementary Methods online.
For all other detail methods, please see the ﬁle ‘Supplemen-
tary Methods’, in the online Supplementary Material.
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